A Phase 2 interventional study of OPC-34712 and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 2nd registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 773 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 13th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is one of 7 in phase 2, and was the 8th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved antidepressant in order to determine if the study medication is effective as an add on treatment of MDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
Drug: OPC-34712 · Drug: Placebo · Drug: ADT
Placebo + ADT
Drug: Placebo · Drug: ADT
Tablets, Oral, 1 - 3 mg OPC-34712
Placebo
Also known as: FDA Approved Antidepressant (ADT)
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
Time frame: Baseline (end of week 8) to Week 14
Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. Scores of 5 and above are associated with significant functional impairment. The SDS total score ranges from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
Time frame: Baseline (end of week 8) to Week 14
Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.
The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
Time frame: Baseline (end of week 8) to Week 14
Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline (end of week 8) to Week 14
Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
The IDS-SR was a 30-item self-report measure, that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). For individual items, the scores range from 0 to 3. The IDS-SR are scored by summing responses to 28 of the 30 items to obtain a total score ranging from 0 to 84, higher values indicate greater disruption in the depressive symptoms.
Time frame: Baseline (end of week 8) to Week 14
Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52.
Time frame: Baseline (end of week 8) to Week 14
Clinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participants total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Baseline (end of week 8) to Week 14
Number of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.
A MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
Time frame: Baseline (end of week 8) to Week 14
Number of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.
A MADRS remission was defined as MADRS Total Score =\< 10 and \>= 50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
Time frame: Baseline (end of week 8) to Week 14
Number of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).
CGI-I Response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
Time frame: Baseline (end of week 8) to Week 14
This trial was conducted in the United States in 773 participants at 44 centers. A total of 1226 participants were screened, 773 participants were enrolled in Phase A, and 769 were treated in Phase A. Of the 623 participants who completed Phase A, 372 participants were randomized in to Phase B.
| Milestone | Phase A | Brexiprazole | Placebo | Phase A+ |
|---|---|---|---|---|
| Started | 769 | 0 | 0 | 0 |
| Completed | 623 | 0 | 0 | 0 |
| Not completed | 146 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 22 | 0 | 0 | 0 |
| Withdrew: Adverse event | 32 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 26 | 0 | 0 | 0 |
| Withdrew: Physician decision | 10 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 29 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 27 | 0 | 0 | 0 |
| Milestone | Phase A | Brexiprazole | Placebo | Phase A+ |
|---|---|---|---|---|
| Started | 0 | 185 | 187 | 0 |
| Completed | 0 | 167 | 171 | 0 |
| Not completed | 0 | 18 | 16 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 | 0 |
| Withdrew: Adverse event | 0 | 9 | 2 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 | 0 |
| Withdrew: Protocol deviation | 0 | 3 | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Milestone | Phase A | Brexiprazole | Placebo | Phase A+ |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 251 |
| Completed | 0 | 0 | 0 | 230 |
| Not completed | 0 | 0 | 0 | 21 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 7 |
The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. | -8.20 ± 0.62 | -7.02 ± 0.62 |
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. Scores of 5 and above are associated with significant functional impairment. The SDS total score ranges from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score. | -0.91 ± 0.19 | -0.69 ± 0.19 |
The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 180) | -3.30 ± 0.42 | -1.99 ± 0.42 |
| Week 10 (N= 184, 181) | -5.92 ± 0.50 | -4.01 ± 0.50 |
| Week 11 (N= 184, 181) | -7.23 ± 0.57 | -5.22 ± 0.57 |
| Week 12 (N= 184, 181) | -8.42 ± 0.59 | -6.21 ± 0.59 |
| Week 13 (N= 184, 181) | -9.00 ± 0.59 | -7.18 ± 0.59 |
| Week 14 (N= 184, 181) | -8.20 ± 0.62 | -7.02 ± 0.62 |
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 180) | -0.29 ± 0.05 | -0.20 ± 0.05 |
| Week 10 (N= 184, 181) | -0.58 ± 0.06 | -0.44 ± 0.06 |
| Week 11 (N= 184, 181) | -0.76 ± 0.07 | -0.59 ± 0.07 |
| Week 12 (N= 184, 181) | -0.94 ± 0.07 | -0.68 ± 0.07 |
| Week 13 (N= 184, 181) | -1.00 ± 0.08 | -0.81 ± 0.08 |
| Week 14 (N= 184, 181) | -0.95 ± 0.08 | -0.85 ± 0.08 |
The IDS-SR was a 30-item self-report measure, that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). For individual items, the scores range from 0 to 3. The IDS-SR are scored by summing responses to 28 of the 30 items to obtain a total score ranging from 0 to 84, higher values indicate greater disruption in the depressive symptoms.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 179) | -1.65 ± 0.54 | -1.99 ± 0.53 |
| Week 10 (N= 184, 181) | -2.91 ± 0.60 | -2.93 ± 0.60 |
| Week 11 (N= 184, 181) | -3.92 ± 0.68 | -3.64 ± 0.68 |
| Week 12 (N= 184, 181) | -4.82 ± 0.74 | -4.76 ± 0.74 |
| Week 13 (N= 184, 181) | -5.60 ± 0.75 | -5.59 ± 0.75 |
| Week 14 (N= 184, 181) | -5.70 ± 0.80 | -5.84 ± 0.80 |
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score. | -5.98 ± 0.45 | -5.40 ± 0.45 |
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participants total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 179) | 3.33 ± 0.82 | 3.37 ± 0.74 |
| Week 10 (N= 184, 180) | 3.03 ± 0.97 | 3.15 ± 0.84 |
| Week 11 (N= 184, 180) | 3.00 ± 1.08 | 3.02 ± 0.99 |
| Week 12 (N= 184, 180) | 2.63 ± 1.12 | 2.91 ± 1.02 |
| Week 13 (N= 184, 180) | 2.60 ± 1.14 | 2.80 ± 1.02 |
| Week 14 (N= 184, 181) | 2.68 ± 1.18 | 2.78 ± 1.07 |
A MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
| participants | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 180) | 11 | 4 |
| Week 10 (N= 184, 181) | 29 | 16 |
| Week 11 (N= 184, 181) | 41 | 26 |
| Week 12 (N= 184, 181) | 56 | 28 |
| Week 13 (N= 184, 181) | 55 | 33 |
| Week 14 (N= 184, 181) | 55 | 36 |
A MADRS remission was defined as MADRS Total Score =\< 10 and \>= 50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.
| participants | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 180) | 7 | 3 |
| Week 10 (N= 184, 181) | 15 | 7 |
| Week 11 (N= 184, 181) | 31 | 18 |
| Week 12 (N= 184, 181) | 42 | 19 |
| Week 13 (N= 184, 181) | 46 | 25 |
| Week 14 (N= 184, 181) | 48 | 27 |
CGI-I Response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
| participants | Brexpiprazole | Placebo |
|---|---|---|
| Week 9 (N= 181, 179) | 23 | 19 |
| Week 10 (N= 184, 180) | 47 | 39 |
| Week 11 (N= 184, 180) | 73 | 51 |
| Week 12 (N= 184, 181) | 88 | 63 |
| Week 13 (N= 184, 181) | 90 | 70 |
| Week 14 (N= 184, 181) | 84 | 72 |
Collected over AEs were recorded from the time the participant entered Phase B, throughout the 6-week treatment period (Week 9 to Week 14) and until follow-up at 30 days after the last dose of medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole | — | 0/185 (0%) | 90/185 (48.6%) |
| Placebo | — | 3/187 (1.6%) | 63/187 (33.7%) |
| Event | Brexpiprazole | Placebo |
|---|---|---|
| Sinus bradycardiaCardiac disorders | 0/185 | 1/187 |
| DepressionPsychiatric disorders | 0/185 | 1/187 |
| HypotensionVascular disorders | 0/185 | 1/187 |
| Subclavian vein thrombosisVascular disorders | 0/185 | 1/187 |
| Event | Brexpiprazole | Placebo |
|---|---|---|
| AkathisiaNervous system disorders | 22/185 | 9/187 |
| Weight increasedInvestigations | 21/185 | 5/187 |
| InsomniaPsychiatric disorders | 17/185 | 6/187 |
| HeadacheNervous system disorders | 9/185 | 16/187 |
| FatigueGeneral disorders | 14/185 | 8/187 |
| Increased appetiteMetabolism and nutrition disorders | 14/185 | 3/187 |
| NasopharyngitisInfections and infestations | 12/185 | 5/187 |
| ConstipationGastrointestinal disorders | 11/185 | 4/187 |
| DiarrhoeaGastrointestinal disorders | 10/185 | 10/187 |
| Upper respiratory tract infectionInfections and infestations | 9/185 | 10/187 |
| Age, Continuous(Years) | Brexpiprazole | Placebo | Total |
|---|---|---|---|
| Mean | 44.7 ± 11.7 | 42.4 ± 11.7 | 43.5 ± 11.8 |
| Sex: Female, Male(Participants) | Brexpiprazole | Placebo | Total |
|---|---|---|---|
| Female | 123 | 130 | 253 |
| Male | 62 | 57 | 119 |
The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 4 years 1 month after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →